'Cures' Would Cost FDA $872 Million, Device Provisions A Big Chunk

'Cures' Would Cost FDA $872 Million, Device Provisions A Big Chunk-insidehealthpolicy: The Congressional Budget Office estimates that provisions in the House 21st Century Cures Act -- including priority review for medical devices and biomarker development language -- would cost FDA $872 million, more than $300 million over what the bill reportedly mandates in funding for the agency and closer to what FDA had estimated the bill would cost the agency. FDA estimated it would cost more than $900 million, according to a Congressional Research Service report.